Literature DB >> 9531012

Progressive multifocal leukoencephalopathy in patients with HIV infection.

J R Berger1, L Pall, D Lanska, M Whiteman.   

Abstract

Progressive multifocal leukoencephalopathy (PML), a formerly rare disease, is estimated to occur in up to 5% of all patients with AIDS. The high prevalence of PML in AIDS patients currently enables a comprehensive evaluation of this disorder. We evaluated the clinical and radiographic features of PML in a large cohort of AIDS patients identified by retrospective chart review from 1981 to 1994. Two hundred and five patients were diagnosed with PML of which 154 met the inclusion criteria. Seventy-two (47%) were pathologically confirmed and the remaining 82 (53%) met clinical and radiographic criteria. There was a 12-fold increase in the frequency of PML between 1981-1984 and 1991-1994. PML affected 136 men and 18 women with AIDS. Eighty-four percent of cases were 20-50 years old (range 5 to 68 years). The most common AIDS risk factors were homosexuality (57%) among men and heterosexual transmission (28%) and intravenous drug abuse (28%) among women. In 27% of patients, PML heralded AIDS. Common manifestations included weakness, gait abnormalities, speech disturbance, cognitive disorders, headache, and visual impairment. The CD4 lymphocyte counts exceeded 200 cells in 11% at the time of presentation. Involvement of posterior fossa structures was evident in 48% of cranial magnetic resonance imaging (MRI) studies, but in only 11% of computed tomographies (CT) of the brain. Contrast enhancement, typically faint and peripheral, was seen in 10% of CT scans and 15% of MRIs. The median survival was 6 months and survival exceeded 1 year in 9%. PML is no longer a rare disease. It often heralds AIDS and may occur in the absence of significant decline in CD4 lymphocytes. Survival is generally poor, although prolonged survival beyond 1 year is not unusual.

Entities:  

Mesh:

Year:  1998        PMID: 9531012     DOI: 10.3109/13550289809113482

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  95 in total

Review 1.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 2.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 3.  Challenges for clinical trials on progressive multifocal leukoencephalopathy.

Authors:  D B Clifford
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 4.  Brain tumors and polyomaviruses.

Authors:  Sidney Croul; Jessica Otte; Kamel Khalili
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

Review 5.  Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

Authors:  K Warnatz; H H Peter; M Schumacher; L Wiese; A Prasse; F Petschner; P Vaith; B Volk; S M Weiner
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

6.  Progressive Multifocal Leukoencephalopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

Review 7.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 8.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

Review 9.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

10.  JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis.

Authors:  Nana Merabova; Dorota Kaniowska; Rafal Kaminski; Satish L Deshmane; Martyn K White; Shohreh Amini; Armine Darbinyan; Kamel Khalili
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.